Protalex, Inc. announced that data highlighting results from its European Phase 1b open-label, dose-escalation study of PRTX-100 in adult patients with persistent/chronic immune thrombocytopenia were presented in a poster at the European Hematology Association 23rd Annual Meeting underway in Stockholm. Company’s lead drug candidate PRTX-100, is a highly purified form of staphylococcal protein. The poster highlights findings from fifteen patients enrolled in all five dose escalating cohorts and included seven women and eight men ages 22 to 82. The primary objective of this study was to evaluate the safety of five different doses of PRTX-100. The data demonstrated that PRTX-100 had an acceptable safety profile across the dose range studied. The data also showed that platelet counts were elevated in most patients that received four weeks of treatment, with six patients having a peak platelet count that was at least double their baseline count. Two patients achieved a per protocol platelet response.